Advertisement

Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis

A Systematic Review and Meta-Analysis

      Background

      Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are two antifibrotic medications currently approved for slowing the rate of lung function decline in IPF, but data on treatment effect on mortality and risk of acute exacerbation (AE) remains limited or unknown.

      Research Question

      Does antifibrotic treatment decrease risk of mortality and AE?

      Study Design and Methods

      A comprehensive search of several databases, including Ovid MEDLINE(R), Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus, was conducted. Studies were included if they were original articles comparing mortality or AE events in IPF patients with and without antifibrotic treatment. Relative risk (RR) with 95%CI was pooled using random-effects meta-analyses with inverse variance method, assessing two primary outcomes of all-cause mortality and AE risk.

      Results

      A total of 12,956 patients across 26 studies (eight randomized controlled trials and 18 cohort studies) were included in the meta-analysis. Antifibrotic treatment was associated with decreased risk of all-cause mortality with a pooled RR of 0.55 (95% CI, 0.45-0.66) and I2 of 82%. This effect was consistent across additional subgroup analyses, including stratification by study type, risk of bias, duration of follow-up, and antifibrotic subtype. Antifibrotic treatment also reduced the risk of AE, with a pooled RR of 0.63 (95% CI, 0.53-0.76), and I2 of 0%. Effect on AE risk was consistent across subgroup analyses by study type and for nintedanib but not for pirfenidone.

      Interpretation

      Antifibrotic treatment appears to reduce the risk of all-cause mortality and AE in IPF. Despite greater heterogeneity with pooled analysis, its effect was robust in subgroup analyses by study type, duration of follow-up, and antifibrotic subtype.

      Key Words

      Abbreviations:

      AE (acute exacerbation), HR (hazard ratio), IPF (idiopathic pulmonary fibrosis), RCT (randomized controlled trial), RR (relative risk)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ryu J.H.
        • Moua T.
        • Daniels C.E.
        • et al.
        Idiopathic pulmonary fibrosis: evolving concepts.
        Mayo Clin Proc. 2014; 89: 1130-1142
        • Hilberg F.
        • Roth G.J.
        • Krssak M.
        • et al.
        BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
        Cancer Res. 2008; 68: 4774-4782
        • Nakayama S.
        • Mukae H.
        • Sakamoto N.
        • et al.
        Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.
        Life Sci. 2008; 82: 210-217
        • King Jr., T.E.
        • Bradford W.Z.
        • Castro-Bernardini S.
        • et al.
        A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
        N Engl J Med. 2014; 370: 2083-2092
        • Richeldi L.
        • du Bois R.M.
        • Raghu G.
        • et al.
        Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
        N Engl J Med. 2014; 370: 2071-2082
        • Wells A.U.
        • Behr J.
        • Costabel U.
        • et al.
        Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.
        Thorax. 2012; 67: 938-940
        • Nathan S.D.
        • Albera C.
        • Bradford W.Z.
        • et al.
        Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
        Lancet Respir Med. 2017; 5: 33-41
        • Lancaster L.
        • Crestani B.
        • Hernandez P.
        • et al.
        Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
        BMJ Open Respir Res. 2019; 6e000397
        • Cerri S.
        • Monari M.
        • Guerrieri A.
        • et al.
        Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment.
        Respir Med. 2019; 159: 105803
        • Fernandez-Fabrellas E.
        • Molina-Molina M.
        • Soriano J.B.
        • et al.
        Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry.
        Respir Res. 2019; 20: 127
        • Sterne J.A.C.
        • Savovic J.
        • Page M.J.
        • et al.
        RoB 2: a revised tool for assessing risk of bias in randomised trials.
        BMJ. 2019; 366: l4898
        • Stang A.
        Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.
        Eur J Epidemiol. 2010; 25: 603-605
        • Islam M.M.
        • Iqbal U.
        • Walther B.
        • et al.
        Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis.
        Neuroepidemiology. 2016; 47: 181-191
        • Sharmin S.
        • Kypri K.
        • Khanam M.
        • Wadolowski M.
        • Bruno R.
        • Mattick R.P.
        Parental supply of alcohol in childhood and risky drinking in adolescence: systematic review and meta-analysis.
        Int J Environ Res Public Health. 2017; 14: 287
        • Atkins D.
        • Best D.
        • Briss P.A.
        • et al.
        Grading quality of evidence and strength of recommendations.
        BMJ. 2004; 328: 1490
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • Azuma A.
        • Nukiwa T.
        • Tsuboi E.
        • et al.
        Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2005; 171: 1040-1047
        • Taniguchi H.
        • Ebina M.
        • Kondoh Y.
        • et al.
        Pirfenidone in idiopathic pulmonary fibrosis.
        Eur Respir J. 2010; 35: 821-829
        • Noble P.W.
        • Albera C.
        • Bradford W.Z.
        • et al.
        Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
        Lancet. 2011; 377: 1760-1769
        • Richeldi L.
        • Costabel U.
        • Selman M.
        • et al.
        Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
        N Engl J Med. 2011; 365: 1079-1087
        • Huang H.
        • Dai H.P.
        • Kang J.
        • Chen B.Y.
        • Sun T.Y.
        • Xu Z.J.
        Double-blind randomized trial of pirfenidone in Chinese idiopathic pulmonary fibrosis patients.
        Medicine (Baltimore). 2015; 94e1600
        • Lancaster L.
        • Goldin J.
        • Trampisch M.
        • et al.
        Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis.
        Open Respir Med J. 2020; 14: 27-31
        • Hosein K.
        • Le J.
        • Mura M.
        Assessing the therapeutic response to pirfenidone in idiopathic pulmonary fibrosis: can we do better than with forced vital capacity alone?.
        Lung. 2017; 195: 101-105
        • Jo H.E.
        • Glaspole I.
        • Grainge C.
        • et al.
        Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
        Eur Respir J. 2017; 49: 02
        • Margaritopoulos G.A.
        • Trachalaki A.
        • Wells A.U.
        • et al.
        Pirfenidone improves survival in IPF: results from a real-life study.
        BMC Pulm Med. 2018; 18: 177
        • Zubairi A.B.S.
        • Ahmad H.
        • Hassan M.
        • et al.
        Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: an experience from a tertiary care center in Pakistan.
        Clin Respir J. 2018; 12: 1191-1196
        • Dempsey T.M.
        • Sangaralingham L.R.
        • Yao X.
        • Sanghavi D.
        • Shah N.D.
        • Limper A.H.
        Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2019; 200: 168-174
        • Kaunisto J.
        • Salomaa E.-R.
        • Hodgson U.
        • et al.
        Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.
        ERJ Open Res. 2019; 5: 00170-2018
        • Zurkova M.
        • Kriegova E.
        • Kolek V.
        • et al.
        Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
        Respir Res. 2019; 20: 16
        • Adegunsoye A.
        • Alqalyoobi S.
        • Linderholm A.
        • et al.
        Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis.
        Chest. 2020; 158: 1526-1534
        • Alhamad E.H.
        • Cal J.G.
        • Alrajhi N.N.
        • Aharbi W.M.
        • Alrikabi A.C.
        • Alboukai A.A.
        Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis.
        Ann Thorac Med. 2020; 15: 208-214
        • Behr J.
        • Prasse A.
        • Wirtz H.
        • et al.
        Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
        Eur Respir J. 2020; 56: 08
        • Dhooria S.
        • Agarwal R.
        • Sehgal I.S.
        • et al.
        A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
        Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37: 148-157
        • Feng H.
        • Zhao Y.
        • Li Z.
        • Kang J.
        Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
        Ther Adv Respir Dis. 2020; 141753466620963015
        • Kang J.
        • Han M.
        • Song J.W.
        Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis.
        Sci Rep. 2020; 10: 15620
        • Moon S.W.
        • Kim S.Y.
        • Chung M.P.
        • et al.
        Longitudinal changes in clinical features, management, and outcomes of idiopathic pulmonary fibrosis: a nationwide cohort study.
        Ann Am Thorac Soc. 2020; 03: 03
        • Nathan S.D.
        • Brown A.W.
        • Mogulkoc N.
        • et al.
        The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis.
        Respir Med. 2020; 170: 106068
        • Suzuki Y.
        • Aono Y.
        • Kono M.
        • et al.
        Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy.
        Respirology. 2020; 23: 23
        • du Bois R.M.
        • Nathan S.D.
        • Richeldi L.
        • Schwarz M.I.
        • Noble P.W.
        Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.
        Am J Respir Crit Care Med. 2012; 186: 712-715
        • Collard H.R.
        • King Jr., T.E.
        • Bartelson B.B.
        • Vourlekis J.S.
        • Schwarz M.I.
        • Brown K.K.
        Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2003; 168: 538-542
        • du Bois R.M.
        • Weycker D.
        • Albera C.
        • et al.
        Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
        Am J Respir Crit Care Med. 2011; 184: 1382-1389
        • Zappala C.J.
        • Latsi P.I.
        • Nicholson A.G.
        • et al.
        Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
        Eur Respir J. 2010; 35: 830-836
        • Skandamis A.
        • Kani C.
        • Markantonis S.L.
        • Souliotis K.
        Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
        J Drug Assess. 2019; 8: 55-61
        • Cameli P.
        • Refini R.M.
        • Bergantini L.
        • et al.
        Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study.
        Front Mol Biosci. 2020; 7: 581828
        • Richeldi L.
        • Cottin V.
        • du Bois R.M.
        • et al.
        Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials.
        Respir Med. 2016; 113: 74-79
        • Collard H.R.
        • Ryerson C.J.
        • Corte T.J.
        • et al.
        Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report.
        Am J Respir Crit Care Med. 2016; 194: 265-275
        • Wollin L.
        • Maillet I.
        • Quesniaux V.
        • Holweg A.
        • Ryffel B.
        Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
        J Pharmacol Exp Ther. 2014; 349: 209-220
        • Iyer S.N.
        • Hyde D.M.
        • Giri S.N.
        Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation.
        Inflammation. 2000; 24: 477-491